- DEAN FOR THERAPEUTIC DISCOVERY
- PROFESSOR Medicine, Liver Diseases
- PROFESSOR Pharmacology and Systems Therapeutics
- Aerodigestive Tract
- Apoptosis/Cell Death
- Cancer Genetics
- Cell Biology
- Cell Transformation
- Developmental Biology
- Epithelial Cells
- Extracellular Matrix
- Growth Factors and Receptors
- Hepatitis C Virus
- Knockout Mice
- Molecular Biology
- Oxidative Stress
- Signal Transduction
- Stem Cells
- Transcription Factors
- Transcriptional Activation and Repression
- Transgenic Mice
- Tumor Suppressor Genes
- Vascular Development
- Wound Healing
Dr. Scott L. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at the Icahn School of Medicine at Mount Sinai. He has performed pioneering research into the underlying causes of scarring, or fibrosis associated with chronic liver disease, affecting millions worldwide. Dr. Friedman was the first to isolate and characterize the hepatic stellate cell, the key cell type responsible for scar production in liver. His work has spawned an entire field that is now realizing its translational and therapeutic potential, with new anti-fibrotic therapies for liver disease reaching clinical trials. Dr. Friedman’s work has been continuously funded by the NIH since 1985; he was awarded his first faculty NIH grant (RO1) in 1986 at the age of 31.
A 1979 graduate of the Icahn School of Medicine at Mount Sinai, he served as the President of Alpha Omega Alpha Honor Society and was an awardee of the Arthur Aufses, Sr. Prize in Surgery. After graduation Dr. Friedman was a Medical Resident at the Beth Israel Hospital, Harvard Medical School, Boston, then a Gastroenterology Fellow at UCSF before assuming a faculty position there which he held for ten years. During a 1995-96 sabbatical from UCSF he was a Senior Fulbright Scholar and Visiting Professor at the Weizmann Institute of Science in Israel, in the laboratory of Professor Moshe Oren. Dr. Friedman has given invited honorary lectures throughout the world and has been a named lecturer or Visiting Professor at over 30 institutions worldwide. He is widely recognized as a dynamic, effective speaker, and is also a respected author, with over 300 peer-reviewed publications. Dr. Friedman was a recipient in 1993 of the Saul Horowitz, Jr. Outstanding Alumnus Award from Mount Sinai. In 2003, Dr. Friedman was honored with the International Hans Popper Award by the Falk Foundation in Freiburg, Germany, in recognition of his outstanding contributions to the understanding of liver disease and its treatment. He has mentored over 75 postdoctoral fellows and students, most of who remain in academic training programs or faculty. In addition to his laboratory research, Dr. Friedman is a respected clinician and teacher, and is listed among the "America’s Top Doctors". He was awarded the Department of Medicine’s Berson Housestaff Teaching Award in 2006, and in 2009 was recognized as a Master Educator by the Mount Sinai Institute of Medical Education. In 2012 he was awarded the European Association for the Study of Liver Diseases International Recognition Award in Barcelona, Spain, and in 2013 he was awarded the Shanghai Magnolia Gold Award by the Mayor of Shanghai and the China Friendship Award from the Premier of China in 2014 in recognition of his efforts to improve the health of the residents of Shanghai and China through his research achievements.
As Chief of the Division of Liver Diseases at Mount Sinai since 2001, Dr. Friedman has expanded the faculty from 5to 25 individuals, increased NIH grant funding more than 5-fold, clinical trials income more than 10-fold, and overseen the creation of the largest liver fellowship in the United States. He is formerly an Associate Editor of Hepatology, and is currently Associate Editor for the Journal of Hepatology, and Series Editor for the Mount Sinai Handbooks of Disease (to be published in 2014), and has served on multiple Editorial Boards. He is on the Scientific Advisory Board of the US-Israel Binational Science Foundation and previously served on the Senior Advisory Council for the National Institute of Alcohol Abuse and Alcoholism. He has been a member of the American Society of Clinical Investigation since 1995, the Association of American Physicians since 2004, and was elected as a Fellow of the American Gastroenterological Association in 2008, the Am. College of Physicians in 2013, the American Association for the Study of Liver Diseases in 2014 and the American Association for the Advancement of Science in 2015.
As President of the American Assn for the Study of Liver Diseases in 2009 (the sixth Mount Sinai faculty member to hold this position), Dr. Friedman oversaw several major new initiatives that accelerated its growth and brought the Association to unmatched levels of growth, income and international visibility.
Most recently, Dr. Friedman’s appointment in 2012 as Dean for Therapeutic Discovery at Mount Sinai recognizes his unique strengths in translating basic science into novel diagnostics and therapeutics. He currently consults for over 40 pharmaceutical and biotech companies and is widely viewed as one of the leading experts in fibrosis in the world. In his role as Dean for Therapeutic Discovery, Dr. Friedman seeks to integrate the rapidly growing innovation ecosystem at Mount Sinai which includes Mount Sinai Innovation Partners, the Center for Technology Innovation and Entrepreneurship, and Experimental Therapeutics core facilities in order to accelerate the discovery, commercialization and translation of novel advances into new treatments for human disease.
Ken & Louise Goldberg Visiting Professor
Brigham and Women’s Hospital
Burton Combes Memorial Lecturer, UT Southwestern School of Medicine
Rao Honorary Lecture, Feinberg School of Medicine, Northwestern U.
American Liver Foundation Salute to Excellence Award, San Francisco
Fellow, American Association for the Advancement of Science
The Jacobi Medallion for dedication and service to Mount Sinai
China Friendship Award, presented by the Premier of China
Fellow, American Association for the Study of Liver Diseases
Shanghai Magnolia Gold Award, for outstanding contributions to Shanghai’s social and economic development, given by the Mayor of Shanghai
Fellow, American College of Physicians
International Recognition Award
European Assn for the Study of Liver
Sheila Sherlock Lecture, British Assn for Gastroenterology, Liverpool, UK
Englert Lecture, University of Utah Dept of Medicine
Rafael Research Alumni Visiting Scientist
Rambam Hospital, Haifa, Israel
American Assn for the Study of Liver Diseases
Master Educator Recognition
Mount Sinai Institute for Medical Education
Sackler Distinguished Lectureship
Tel Aviv University, Israel
Dean's Distinguished Lecturer
Georgetown U. School of Medicine
Natl Institute on Alcohol Abuse and Alcoholism
Fellow of the American Gastroenterological Assn
America's Top Doctors
Solomon Berson Dept of Medicine Housestaff Teaching Award
John Carbone Visiting Professor
Medicine, NY, NY
Lieberman Memorial Lecture
Lenox Hill Hospital Dept of Medicine, NY, NY
International Hans Popper Award to Outstanding Researcher in Hepatology
International Hans Popper Award to Outstanding Researcher in Hepatology
Jacobson Visiting Professor and Lecturer
U. of Newcastle School of Medicine
Charles Flood Memorial Lecture
NY Cornell Presbyterian Hosp. GI Division
Ernest Hafter Memorial Lecture
Swiss Gastroenterological Association
Irene and Dr. Arthur Fishberg Professor of Medicine
Mount Sinai School of Medicine
Fulbright Senior Scholar Award
Saul Horowitz Outstanding Alumnus Award
Mount Sinai School of Medicine
'Bay Area's Best Doctors'
San Francisco Focus Magazine
Arthur H. Aufses Sr., Prize in Surgery
Mount Sinai School of Medicine
Alpha Omega Alpha, Lambda Chapter
Rensselaer Polytechnic Institute
ResearchDr. Friedman is the Director of both the Fibrosis Research Center and the Mount Sinai Alcoholic Liver Disease Research Center.
Specific Clinical/Research Interest:
1) Role of KLF6 tumor suppressor gene in cancer pathogenesis;
2) Molecular regulation of hepatic fibrosis;
3) Testing of novel antifibrotic therapies in preclinical models and human trials
Current Students: MD/PhD: Ursula Lang, Zhara Ghiassi-Nejad, Yedidya Saiman (co-mentor); Ph.D. - Jingjing Jiao (co-mentor_; Doris Duke Medical Student Research Fellow: Andrew Paris
Postdoctoral Fellows: Lars Bechmann, M.D.; Beatriz Minguez, M.D.; Sara Tofannin, Ph.D.; Rebekka Hannivoort, M.D.; Ursula Munoz, PhD; Diana Vetter M.D.
Research Personnel: Johnny Loke, M.S. (Lab Manager); Feng Hong M.D.
Summary of Research Studies:
-Role of KLF6 in Cell Growth and Human Cancer.
We have cloned a novel Kruppel like factor, KLF6, from liver that is ubiquitously expressed, and mutated in a number of human cancers. Major KLF6-related research projects are:
-Identification of KLF6 transcriptional targets by array
-Role of KLF6 in liver development
-Inactivation of KLF6 in human cancers, esp. hepatocellular carcinoma
-Animal models of cancer with KLF6 dysregulation
-KLF6 Interacting proteins
-Animal models of KLF6 dysregulation (tissue specific KO; KLF6 +/- mice responses to injury and carcinogens) Molecular Regulation of Hepatic Fibrosis.
Our work explores the molecular mechanisms of wound healing and fibrosis in liver. We use a variety of animal and cell culture models to identify key inflammatory mediatiors and signaling molecules regulating the activation of hepatic stellate cells, the principle fibrogenic cells in liver. Additionally, we test candidate antifibrotic lead compounds to develop potential new therapies for patients with chronic fibrosing liver diseases. Specific projects include:
-Testing of antifibrotic lead compounds in animal models
-Clinical trials of antifibrotic therapies in patients with chronic liver disease
-Exploration of mechanisms underlying risk-associated genes in hepatic fibrosis
-Role of KLF6 splicing in hepatic stellate cell activation
Bechmann LP, Vetter D, Ishida J, Hannivoort RA, Lang UE, Kocabayoglu P, Fiel MI, Muñoz U, Patman GL, Ge F, Yakar S, Li X, Agius L, Lee YM, Zhang W, Hui KY, Televantou D, Schwartz GJ, LeRoith D, Berk PD, Nagai R, Suzuki T, Reeves HL, Friedman SL. Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. Journal of hepatology 2013 May; 58(5).
Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013 May; 144(5).
Weiskirchen R, Weimer J, Meurer SK, Kron A, Seipel B, Vater I, Arnold N, Siebert R, Xu L, Friedman SL, Bergmann C. Genetic characteristics of the human hepatic stellate cell line LX-2. PloS one 2013; 8(10).
King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X, Villanueva A, Sangiovanni A, Nair V, Mahajan M, Kobayashi M, Kumada H, Iavarone M, Colombo M, Fiel MI, Friedman SL, Llovet JM, Chung RT, Hoshida Y. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut 2014 Aug;.
Lee JM, Yang J, Newell P, Singh S, Parwani A, Friedman SL, Nejak-Bowen KN, Monga SP. β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer letters 2014 Feb; 343(1).
Kocabayoglu P, Lade A, Lee YA, Dragomir AC, Sun X, Fiel MI, Thung S, Aloman C, Soriano P, Hoshida Y, Friedman SL. β-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis. Journal of hepatology 2015 Feb;.
Lu J, He L, Behrends C, Araki M, Araki K, Jun Wang Q, Catanzaro JM, Friedman SL, Zong WX, Fiel MI, Li M, Yue Z. NRBF2 regulates autophagy and prevents liver injury by modulating Atg14L-linked phosphatidylinositol-3 kinase III activity. Nature communications 2014; 5.
Son BK, Sawaki D, Tomida S, Fujita D, Aizawa K, Aoki H, Akishita M, Manabe I, Komuro I, Friedman SL, Nagai R, Suzuki T. Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural haematoma. Nature communications 2015; 6.
Hasegawa D, Calvo V, Avivar-Valderas A, Lade A, Chou HI, Lee YA, Farias EF, Aguirre-Ghiso JA, Friedman SL. Epithelial Xbp1 Is Required for Cellular Proliferation and Differentiation during Mammary Gland Development. Molecular and cellular biology 2015 May; 35(9).
Zhang D, Goossens N, Guo J, Tsai M, Chou H, Altunkaynak C, Sangiovanni A, Ivarone M, Colombo M, Kobayashi M, Kumada H, Villanueva A, Llovet J, Hoshida Y, Friedman S. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. . Gut 2015;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Friedman during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- AbbVie Inc.; Alnylam Pharmaceuticals; BiOrion Technologies BV; Blueprint Medicines; Boehringer Ingelheim Corporation; Bristol-Myers Squibb; Conatus Pharmaceuticals; Deerfield Consulting; Exalenz Bioscience Ltd.; Genentech, Inc.; GlaxoSmithKline; InterMune; KineMed; Nimbus Discovery LLC; Ocera Therapeutics Inc.; PharmaStrat; Regado Biosciences, Inc.; RuiYi, Inc.; Sandhill Scientific Inc.; Synageva BioPharma; Teva Pharmaceutical Industries Ltd.; Tobira Therapeutics, Inc.; sanofi-aventis
Scientific Advisory Board:
- Galectin Therapeutics; Intercept Pharmaceuticals Inc.; Nitto Denko Corporation; Pfizer Inc.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Galectin Therapeutics; Tobira Therapeutics, Inc.; Vaccinex Inc.
- Chugai Pharmaceutical Co., Ltd.; F. Hoffman-La Roche Ltd.; Life Technologies Corporation; Mitsubishi Tanabe Pharma Corporation; Nitto Denko Corporation; Novartis
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Angion Biomedica Corp; Galectin Therapeutics; KineMed; Nimbus Discovery LLC; Tobira Therapeutics, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 11th Floor Room Room 11-70C
1425 Madison Avenue
New York, NY 10029